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Abstract
Background: Microglial activation and the proinflammatory response are controlled by a complex regulatory
network. Among the various candidates, macrophage colony-stimulating factor (M-CSF) is considered an important
cytokine. The up-regulation of M-CSF and its receptor CSF-1R has been reported in brain disease, as well as in
diabetic complications; however, the mechanism is unclear. An elevated level of glycated albumin (GA) is a
characteristic of diabetes; thus, it may be involved in monocyte/macrophage-associated diabetic complications.
Results: The basal level of expression of M-CSF/CSF-1R was examined in retinal microglial cells in vitro.
Immunofluorescence, real-time PCR, immunoprecipitation, and Western blot analyses revealed the up-regulation of
CSF-1R in GA-treated microglial cells. We also detected increased expression and release of M-CSF, suggesting that
the cytokine is produced by activated microglia via autocrine signaling. Using an enzyme-linked immunosorbent
assay, we found that GA affects microglial activation by stimulating the release of tumor necrosis factor-a and
interleukin-1b. Furthermore, the neutralization of M-CSF or CSF-1R with antibodies suppressed the proinflammatory
response. Conversely, this proinflammatory response was augmented by the administration of M-CSF.
Conclusions: We conclude that GA induces microglial activation via the release of proinflammatory cytokines,
which may contribute to the inflammatory pathogenesis of diabetic retinopathy. The increased microglial
expression of M-CSF/CSF-1R not only is a response to microglial activation in diabetic retinopathy but also
augments the microglial inflammation responsible for the diabetic microenvironment.
Background
Recent evidence strongly suggests that microglial activa-
tion plays a central role in the inflammation induced by
experimental and human retinopathy [1-4]. Microglia,
the resident macrophages of the central nervous system
(CNS), is sensitive to minute changes in their microen-
vironment and is quickly activated. Upon activation,
they proliferate and become amoeboid phagocytotic
cells that produce a variety of proinflammatory cyto-
kines, nitric oxide (NO), and reactive oxygen intermedi-
ates [5-7]. These factors are well known to induce
neurodegeneration, although the precise mechanism is
not fully understood.
Recently, Wang et al. [8] reported that glycated albu-
min (GA) significantly enhanced the production and
release of tumor necrosis factor-a (TNF-a) from retinal
microglia in vitro, suggesting that GA contributes to
microglial inflammation in diabetic retinopathy. Chronic
hyperglycemia in diabetes, through the nonenzymatic
glycation of free amino groups in proteins by glucose,
leads to the formation of labile Schiff base intermediates
that undergo Amadori rearrangement, leading to the
relatively stable early adducts ketoamine or fructosamine
(so-called Amadori products). Eventually, these Amadori
products form irreversible advanced glycation end pro-
ducts (AGEs) [9]. Glycated albumin levels increase dras-
tically under diabetic conditions, and the plasma levels
of GA may vary from normal (400 μg/mL) to diabetic
(1000 μg/mL) [10]. Increasing evidence suggests that
early glycated albumin is not just an index of glycemia
or the precursor of AGEs. By itself, it may have direct
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impacts on cellular functions and thus may play a
pathophysiological role in microvascular complications
of diabetic nephropathy and retinopathy [11-14]. Gly-
cated albumin accumulates in the diabetic retina [14-16]
and changes the local concentrations of cytokines,
growth factors, and other bioactive molecules by binding
on several cell types, such as retinal pigment epithelium
cells [17,18] and monocytes/macrophages [19,20], and
by inducing the secretion of proinflammatory cytokines
via the activation of protein kinase C (PKC), nuclear fac-
tor-B (NF-B), protein tyrosine kinase (PTK), and acti-
vator protein-1 (AP-1) signaling [21,22]. Therefore, GA
may have important effects on the initiation and pro-
gression of diabetic retinopathy.
Macrophage colony-stimulating factor (M-CSF) is one
of the most important substances known to affect
macrophage physiology. The binding of M-CSF to its
sole specific receptor, CSF-1R, stimulates the survival,
proliferation, and differentiation of mononuclear phago-
cytes [23,24]. Moreover, M-CSF is considered a key
cytokine in the regulation of microglial inflammatory
responses [25]. Accumulating evidence suggests the up-
regulation of M-CSF accompanied by the strong and
selective induction of CSF-1R in activated microglia fol-
lowing brain damage caused by injury or disease such as
brain ischemia or Alzheimer’s disease [26-29]. In vitro,
microglial overexpression of CSF-1R augments phagocy-
tosis and contributes to the inflammatory response
[30,31]. Similar patterns of M-CSF/CSF-1R expression
have also been reported in the diabetic environment,
suggesting that M-CSF/CSF-1R signaling plays a critical
role in the pathogenesis of diabetic lesions [32,33]. The
exact mechanism, however, is unclear.
Given the small amount of information available con-
cerning CSF-1R expression by microglia in the diabetic
environment, the regulatory role of M-CSF/CSF-1R sig-
naling in microglial inflammation in diabetic retinopathy
is unknown. In the present study, we sought to ascertain
whether GA has an effect on retinal microglial activation,
including the production of proinflammatory cytokines,
as well as the expression of M-CSF and its receptor CSF-
1R. Furthermore, using exogenous M-CSF and antibody
neutralization, we assessed the combined effect of
M-CSF and GA on the proinflammatory response
in primary microglial cells. Our results indicate that
M-CSF acts as a costimulatory molecule to synergize
GA-induced microglial inflammation via binding to its
overexpressed receptor CSF-1R in diabetic retinopathy.
Results
Morphology and characterization of cultured newborn rat
microglia
After 7 to 8 days of mixed-cell culture, the microglia
appeared in small colonies (about 2 to 5 cells) of highly
refractive cells above the basal macroglial layer. These
round microglial cells or colonies were loosely attached
to the macroglial monolayer; maximum proliferation
was observed within 10 to 12 days. The purified micro-
glial cells went from being amoeboid in shape to having
a ramified shape, with a single long process and a small
cell soma, over the course of 2 to 3 days. Immunofluor-
escence analysis revealed that OX-42-positive microglial
cells accounted for 95% of the harvested cells, whereas
none of the cells was positive for GFAP.
Effects of various agents on microglial viability by MTT
assay
M-CSF-induced microglial proliferation in a dose-
dependent manner was confirmed, in which the extent
of microglial proliferation correlated well with the
increase of the viability measured by MTT assay. In
contrast to M-CSF, GA didn’t induce significant prolif-
eration (Figure 1A). Furthermore, the microglial apopto-
sis was observed when the concentration of GA exceeds
1000 μg/mL. In addition, the antibodies of either
M-CSF or CSF-1R have no effect on microglial viability
by MTT assay (Figure 1B).
GA causes morphological changes in microglial cells
As shown in Figure 2, the unstimulated microglia had a
ramified shape in vitro (Figure 2A). In contrast, the
GA-stimulated microglia was bigger and rounder, with
the appearance of activated cells (Figure 2B).
Effect of GA on the expression of microglial Iba1
Iba1, a microglia-specific calcium-binding protein and
marker of activated microglia, is involved in motility,
phagocytosis, and proinflammation in activated micro-
glia via the regulation of the actin cytoskeleton [34]. In
this study, we observed enhanced Iba1 expression in
GA-stimulated microglia compared with unstimulated
cells. In addition, following 24 h of stimulation with GA,
Iba1 was translocated from the cytoplasm to membrane
ruffles (Figure 2C, 2D).
GA-induced release of TNF-a and interleukin (IL)-1b from
activated microglia
Following stimulation with 10 μg/mL GA for 6 h, a sig-
nificant increase in the release of TNF-a was detected
compared with the control group (38.7 ± 3.2 vs. 19.7 ±
1.7pg/mL; P < 0.05). Moreover, GA induced the dose-
dependent release of TNF-a, with a peak at 250 μg/mL
(138.2 ± 6.6pg/mL; P < 0.0001). There was a slight
increase in the release of TNF-a from 6 to 24 h; how-
ever, no statistically significant difference was found
among the various groups (Figure 3A). Similarly, GA
induced the dose-dependent release of IL-1b. Different
from the release of TNF-a, the increase of IL-1b
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following stimulation with 10 μg/mL GA was not signif-
icant compared with that in the control group until
after 12 h (78.1 ± 3 vs. 50.8 ± 6.8pg/mL; P < 0.05). The
release of IL-1b peaked at 261.3 ± 11.4pg/mL following
12 h of stimulation with 250 μg/mL GA (P < 0.0001);
however, no statistically significant difference was found
among the various groups (Figure 3B). Neither TNF-a
nor IL-1b production by activated microglia stimulated
with GA could be prevented by the endotoxin binding
polypeptide polymyxin B (PMXB) at 10 μg/mL, a dosage
previously reported to abrogate LPS-induced effects on
microglia [35] (Figure 4).
GA-induced production of M-CSF by activated microglia
M-CSF production occurs via autocrine signaling in
activated microglia. To determine whether GA could
induce microglial production of M-CSF, we analyzed the
amount of M-CSF in the microglial culture medium.
After stimulation with 10 or 250 μg/mL GA for 24 h, a
significant increase in M-CSF release (86.4 ± 4.8 or 97.4 ±
7.3 pg/mL, respectively) was detected, compared with the
control (54.8 ± 1.6 pg/mL) (P < 0.05; Figure 5).
GA-induced up-regulation of CSF-1R and tyrosine-
phosphorylation of CSF-1R by activated microglia
Previous studies showed that CSF-1R expression is
enhanced in activated microglia and that this up-regula-
tion not only induces the microglial production of
proinflammatory cytokines but also promotes the pha-
gocytosis of amyloid b (Ab). We analyzed the effect of
GA on CSF-1R expression in microglia. CSF-1R mRNA
was detected in unstimulated microglia; however, after
24 h of stimulation with 10, 250, or 500 μg/mL GA, the
level of CSF-1R mRNA expression was increased 1.2-,
2.1-, and 2.6-fold, respectively (P < 0.05; Figure 6).
To examine the effect of GA on CSF-1R signaling, we
incubated microglial cells with 0, 250, or 500 μg/mL GA
for 24 h, and then subjected them to immunoprecipita-
tion and immunoblot analysis. Our results indicate that
both CSF-1R and phosphorylation of CSF-1R (tyr273)
was up-regulated by GA-activated microglia (Figure 7).
Immunocytochemical analysis further demonstrated
that GA induces the expression of CSF-1R (Figure 8A,
8B), as well as M-CSF (Figure 8C, 8D), in activated
microglia. As shown in Figure 8, enhanced staining was
observed in the GA-stimulated round amoeboid micro-
glia, whereas weak staining was detected in the unstimu-
lated ramified microglia.
Inhibition of M-CSF or CSF-1R signaling suppresses
GA-induced microglial inflammation
We next tested our hypothesis that M-CSF/CSF-1R sig-
naling promotes the release of proinflammatory cyto-
kines in GA-stimulated microglia. We neutralized the
activity of M-CSF or CSF-1R by using anti-M-CSF or
anti-CSF-1R antibodies. The neutralization of M-CSF or
CSF-1R had no effect on unstimulated microglia; how-
ever, both antibodies decreased the release of TNF-a
and IL-1b from the GA-stimulated microglia (Figure 9).
M-CSF augments GA-induced microglial inflammation
To further understand the combined effects of M-CSF
and GA on the proinflammatory response in microglial
cells, we included M-CSF in the microglial culture med-
ium. M-CSF alone did not induce cytokine release; how-
ever, costimulation with M-CSF and GA for 24 h
produced a significant increase in the release of TNF-□
and IL-1b (P < 0.05; Figure 9).
Discussion
Inflammation involving vessels and neural tissue occurs
early in diabetic retinopathy, while excessive and
Figure 1 Effect of M-CSF, glycated albumin (GA) and the
antibodies of either M-CSF(anti-M-CSF Ab)or CSF-1R(anti-CSF-
1R Ab) on microglial viability. After incubated with various stimuli
such as M-CSF or GA (A), and anti-M-CSF Ab (1 μg/ml) or anti-CSF-
1R Ab (1 μg/ml) (B) for 24 h, the cell viability was assessed by MTT
assay. The gradient concentrations of stimuli were: 5, 10, 25, 50, 100
ng/ml for M-CSF; and 10, 50, 100, 500, 1000, 2000 μg/ml for GA. The
results are shown as means ± SD of three individual experiments.
Only M-CSF induced microglial proliferation in a dose-dependent
manner, other agents have no effects on microglial viability. One-
way ANOVA was performed, followed by post-hoc analysis. *, P <
0.05; **, P < 0.005.
Liu et al. BMC Cell Biology 2011, 12:5
http://www.biomedcentral.com/1471-2121/12/5
Page 3 of 11
persistent microglial activation is believed a major con-
tributor to the inflammatory responses [2,36,37]. Micro-
glial activation occurs via a complex regulatory system
involving multiple signals; however, the mechanism
remains to be determined.
Amadori-glycated proteins and the early nonenzymatic
glycation of proteins are increased in diabetes and have
been independently associated with microvascular com-
plications [14,15,38]. As the breakdown of the blood-ret-
inal barrier (BRB) is a characteristic early event, the
increased GA in plasma may penetrate from the com-
promised BRB and accumulate in retinal parenchyma,
influencing the types of retinal cells and molecular med-
iators that subsequently promoting the development of
diabetic retinopathy [17,18,39,40]. Our data suggested
that in vitro GA activate microglia, producing proin-
flammatory factors. This event may be expected to
occur in vivo, thereby aggravate the pathological inflam-
matory process. It was supported by the recent investi-
gation that inhibiting the formation of GA would
ameliorate the development of diabetic retinopathy [15].
The GA used in this study was produced commer-
cially less than 1 week prior and purified to exclude
residual contamination with AGEs as described by
Baynes et al [41]. In contrast to AGEs, only a few stu-
dies have emphasized the role of GA, despite the fact
that the Amadori product is a major form of glycated
proteins and the concentration of GA exceeds that of
AGEs [14,42]. Amadori-modification is structurally dis-
tinct from AGEs, and can bind to monocytes/
Figure 2 Effect of glycated albumin (GA) on cultured retinal microglial cells. (A) Phase-contrast image of purified retinal microglial cells
after 72 h. The cells have a ramified shape, with a single long process and a small cell body (short arrow). (B) Following exposure to 250 μg/mL
GA for 24 h, the cells became rounder, larger, and amoeboid in shape (long arrow) (original magnification: × 100). (C) Microglial cells without GA
exposure show weak Iba1 immunofluorescence (red) in the cytoplasm. (D) Following exposure to 250 μg/mL GA for 24 h, Iba1 expression was
up-regulated, and the protein was translocated to membrane ruffles. The nuclei of the microglia are labeled with DAPI (blue).
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macrophages via specific receptors [19,20]. These recep-
tor proteins have been characterized and the amino acid
sequence homologies were not found in any of the AGE
receptors [19-21,43]. Therefore, it is reasonable that
binding of GA to microglia via specific receptors rather
than receptors of AGEs, induced microglial activation.
Accumulating evidences showed M-CSF is a key cyto-
kine in the regulation of the microglial activation, prolif-
eration and migration in CNS [23-25]. Moreover, the
high-affinity binding of M-CSF to CSF-1R plays a role
in mononuclear/macrophage-associated diabetic compli-
cations, including diabetic retinopathy [32,33,44,45]. Our
previous study provided the evidence that the vigorous
expression of M-CSF/CSF-1R occurred in the early dia-
betic retina and a robust induction of CSF-1R was
observed on the activated microglia [46]. Furthermore,
as shown in the current study, primary retinal microglial
cells express either CSF-1R or M-CSF, albeit at relatively
low baseline levels. While they were exposed to gradient
Figure 3 Cytokine release from purified microglial cells stimulated with glycated albumin (GA) for 6, 12, or 24 h. (A) The release of
TNF-a from retinal microglial cells cultured with 0, 10, 50, 100, or 250 μg/mL GA for various time periods. TNF-a in the culture supernatants
began to increase at 6 h after exposure to 10 μg/mL GA and peaked after exposure to 250 μg/mL GA. (B) The release of IL-1b from retinal
microglial cells cultured with 0, 10, 50, 100, or 250 μg/mL GA for various time periods. IL-1b in the culture supernatants began to increase at
12 h after exposure to 10 μg/mL GA and peaked after exposure to 250 μg/mL GA. The results are shown as means ± SD of three individual
experiments. One-way ANOVA was performed, followed by post-hoc analysis. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
Figure 4 Effect of the endotoxin-binding polypeptide
polymyxin B (PMXB) on cytokine production by microglia
stimulated with glycated albumin (GA) for 24 h. Neither TNF-a
nor IL-1b production induced by 250 μg/mL GA was inhibited by
PMXB (10 μg/mL). Unstimulated microglia was as a control. The
results are shown as means ± SD of three individual experiments.
One-way ANOVA was performed, followed by post-hoc analysis.
*, P < 0.0001.
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concentrations of GA, the enhanced expression of CSF-
1R signaling was detected in activated microglia, not
only at the mRNA but also at the protein level. This up-
regulation is consistent with that as seen in vivo, and
may be integral to diabetic microglial activation [46]. In
light of the above findings, we hypothesize that M-CSF
signaling is a possible molecular pathway in diabetic
retinopathy.
To further our understanding, we measured the
amounts of TNF-a and IL-1b, two important proflam-
matory cytokines secreted by activated microglia, in
GA-stimulated microglial cultures treated with or
without additional M-CSF. Our results show that M-
CSF enhances the production of proflammatory cyto-
kines in GA-activated microglia. M-CSF alone, however,
did not induce the proinflammatory responses but pro-
liferate microglia as shown by MTT assay. Although
theoretically, more cells due to M-CSF treatment may
contribute to more cytokine production, given the fact
that this inducible proinflammation could be signifi-
cantly inhibited by antibody neutralization of M-CSF or
CSF-1R, and the fact that GA enhanced expression of
M-CSF/CSF-1R by microglia, it is reasonable that this is
quite far from the actual synergistic effects of the two
agents. Taken all together, we concluded that M-CSF
may be a co-stimulator with GA and that M-CSF/CSF-
1R signaling exerts a synergistic effect with GA on the
production of proinflammatory cytokines, not simply
due to effects on cell proliferation.
Astrocytes, a major source of M-CSF in CNS, can be
induced to release M-CSF by proinflammatory cytokines
[47-50]. However, note that M-CSF is also secreted by
activated microglial cells [26,28]. Moreover, as deter-
mined by immunocytochemistry and ELISA, the level of
M-CSF elevates in GA-stimulated-microglia. Elevated
M-CSF expression could cause further reactive micro-
gliosis, phagocytosis, and the release of inflammatory
cytokines such as IL-1b, IL-6, and M-CSF [23-25]. Thus,
the present study provides evidence for the roles of
M-CSF and its signaling cascade in activated microglia
in response to GA stimulation, suggesting that M-CSF
is an important cross-talk mediator, involved in astro-
cytes, neurons, and microglia.
Conclusions
In summary, it is evident that GA can induce microglial
activation by stimulating the release of proinflammatory
Figure 5 M-CSF release from purified microglial cells
stimulated with 0, 10, or 250 μg/mL glycated albumin (GA) for
24 h. GA significantly induces the release of M-CSF, compared with
the control. The results are shown as means ± SD of three
individual experiments. One-way ANOVA was performed, followed
by post-hoc analysis. *, P < 0.05.
Figure 6 Glycated albumin induces the up-regulation of CSF-
1R mRNA expression in purified microglial cells. Microglial cells
were incubated with or without GA at indicated concentrations for
24 h, up-regulation of CSF-1R mRNA expression in microglia was
observed. One-way ANOVA was performed, followed by post-hoc
analysis. *, P < 0.0001.
Figure 7 Glycated albumin (GA) induces the up-regulation of
CSF-1R and tyrosine-phosphorylation of CSF-1R in purified
microglial cells. Microglial cells were incubated with or without GA
for 24 h and then subjected to immunoprecipitation (IP) with
antibodies against phospho-CSF-1R(Tyr723) and then blot with
antibodies against phospho-CSF-1R(Tyr723) or CSF-1R. The
expression of b-actin was used as loading control.
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cytokines such as TNF-a and IL-1b in vitro. Simulta-
neously, up-regulation of CSF-1R on microglia may aug-
ment the overall inflammatory response by propagating
the proinflammatory signal to nearby resting microglia
and astrocytes. The binding of M-CSF to overexpressed
CSF-1R seems to augment GA-induced microglial
inflammation via autocrine and paracrine effects, which
can be blocked by antibody neutralization. Our present
study demonstrate that M-CSF/CSF-1R signaling repre-
sents a further link between microglial inflammation
and diabetic retinopathy and raises the possibility of
specific therapies for targeting microglia-mediated injury
in diabetic retinopathy. Further work are required for a
better understanding of the molecular mechanisms
underlying M-CSF/CSF-1R signaling in microglia
activation.
Methods
Primary Retinal Microglial Culture
Primary mixed glial cell cultures were prepared as
described previously with modifications [51,52]. In
brief, fresh retinas were obtained from newborn Spra-
gue-Dawley rats (2-3 days old). Animal care proce-
dures and the experimental protocol complied with the
Guidelines of the Ethics Committee at Fudan Univer-
sity. The retinas were placed on ice in Ca2+- and Mg2
+-free Hank’s balanced salt solution after removal of
the blood vessels. The tissues were then minced and
exposed to 0.25% trypsin-EDTA (Invitrogen, Carlsbad,
CA) at 37°C for 8 min. After terminating the digestion
with fetal bovine serum (FBS, Invitrogen), the cells
were collected by centrifugation, re-suspended in Dul-
becco’s modified Eagle’s medium (DMEM)/F12 (1:1)
Figure 8 Effect of glycated albumin (GA) on microglial CSF-1R and M-CSF expression. (A) Without GA exposure, microglial cells exhibited
weak CSF-1R immunofluorescence in the cytoplasm. (B) Following exposure to 250 μg/mL GA for 24 h, the expression of CSF-1R was clearly up-
regulated. (C) Similarly, weak M-CSF immunofluorescence was observed in the cytoplasm without GA treatment. (D) Following exposure to 250
μg/mL GA for 24 h, the expression of M-CSF was up-regulated; the signal was detected in both the cytoplasm (long arrow) and nucleus (short
arrow) of each cell.
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(Invitrogen) supplemented with 10% FBS, penicillin/
streptomycin (100 U/100 μg per mL), and L-glutamine
(2 mM), and plated on poly L-lysine-coated (Sigma-
Aldrich, St. Louis, MO) T75 flasks at a density of 1.2 ×
106 cells/mL. The culture medium was changed after 3
days and then twice a week. Upon confluence (7-10
days), the microglial cells were harvested by the “shak-
ing-off” method (an initial shake at 100 rpm for 30
min followed by a second shake 7 days later). The pur-
ified microglial cells were then reseeded in 24-well
plates or T25 flasks (Corning, Inc., Corning, NY). The
purity of the cells was assessed by immunocytochemis-
try using the monoclonal antibody OX-42 (a microglial
marker for complement type 3 receptor) and anti-glial
fibrillary acidic protein antibodies (GFAP) (an astrocyte
marker). Cellular morphology was examined under a
phase-contrast microscope.
Assessment of viabilities by MTT assay
For MTT assay, microglia (2.5 × 104 cells in 200 μl/well)
were seeded in 96-well plates for 24 h and treated with
various stimuli for 48 h. After the treatment, the med-
ium was removed and MTT (5 mg/mL, 20 μl/well) was
added, followed by incubation at 37°C for 4 h. After-
ward, supernatants were carefully removed and DMSO
(150 μl/well, Sigma-Aldrich, St. Louis, MO) was added
to the cells. After insoluble crystals were completely dis-
solved, absorbance at 490 nm was measured using Ther-
momax microplate reader (Molecular Devices).
GA-Induced Retinal Microglial Activation
Purified microglial cells were seeded into T25 flasks.
After 48 h of growth, the cells were incubated with
serum-free DMEM/F-12 containing 0, 10, 50, 100, or
250 μg/mL human GA for 24 h. The GA used in this
study (glycated human serum albumin from Sigma-
Aldrich) was made less than 1 week prior as described
by Baynes et al. [41], and contained 2.7-3.5 mol of
fructoselysine per mol of albumin. No measurable
AGEs were detected in these products by fluorescence
assay (from 360 to 600 nm) with excitation at 370 or
350 nm, or by Western blot analysis [18,53,54]. To
rule out the possible effects of lipopolysaccharide
(LPS) contamination as a potential activator of micro-
glia, microglial cells were also incubated with 250 μg/
mL GA for 24 h in the absence or presence of 10 μg/
mL PMXB (Sigma-Aldrich). Each experiment was per-
formed in triplicate.
M-CSF Treatment
Recombinant murine M-CSF (R&D Systems, Minneapo-
lis, MN) was added at a concentration of 50 ng/mL to
the cell medium with or without 250 μg/mL human GA.
The cells were then allowed to grow for 24 h.
M-CSF and CSF-1R Neutralization
For neutralization, 1 μg/mL anti-M-CSF or anti-CSF-1R
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA)
were added to the cell medium. After 2 h of preincuba-
tion at 37°C, an additional 250 μg/mL human GA were
added to the medium.
Immunocytochemistry
For immunocytochemistry, 12-mm glass coverslips
coated with poly L-lysine were used. Cells were fixed
with 4% paraformaldehyde in 0.1 M phosphate buffer
for 15 min at room temperature, washed in 0.01 M
phosphate-buffered saline (PBS, pH 7.4), blocked in 5%
bovine serum for 30 min, and incubated overnight with
the primary antibodies. The following antibodies were
used: OX-42 (1:200 dilution; Chemicon, Temecula, CA),
Iba1 (1:200; Abcam, Cambridge, UK), M-CSF (1:100;
Santa Cruz Biotechnology), and CSF-1R (1:100; Santa
Cruz Biotechnology). After three rinses with 0.01 M
PBS, fluorescein isothiocyanate (FITC)-conjugated anti-
mouse antibodies (1:200; Sigma-Aldrich), tetramethyl
rhodamine isothiocyanate (TRITC)-conjugated anti-goat
antibodies (1:200; KPL), or Cy3/IgG-conjugated anti-
rabbit antibodies (1:200; Sigma-Aldrich) were added as
secondary antibodies, and the cells were incubated at
37°C for 1 h. To visualize the nuclei, 4’, 6-diamidino-2-
phenylindole (DAPI, 1:500; Sigma-Aldrich) was used.
Images were acquired using a fluorescence microscope or
laser confocal microscope (TCS SP2; Leica Microsystems,
Figure 9 Release of TNF-a and IL-1b from microglia following
the neutralization of M-CSF or CSF-1R, or the administration of
M-CSF. None of the above had a significant effect on cytokine
release in the groups without glycated albumin (GA) stimulation.
The neutralization of M-CSF (1 μg/mL) or CSF-1R (1 μg/mL)
suppressed TNF-a and IL-1b release in the experimental group (cells
treated with 250 μg/mL GA for 24 h). Treatment with 100ng/mL M-
CSF augmented the GA-induced release of TNF-a and IL-1b. One-
way ANOVA was performed, followed by post-hoc analysis. *, P <
0.05; **, P < 0.001, compared with the control group.
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Mannheim, Germany). The optical sections were recon-
structed with a maximum projection using the software
provided with the microscope (Leica Microsystems).
Real-Time PCR
Purified microglial cells were starved of serum for 6 h
and then restimulated with graded GA for 24 h. The
microglia was then sorted into RNA lysis buffer, frozen
on dry ice, and kept at -80°C until processing. Total
RNA was isolated with Trizol reagent (Invitrogen). The
quality and quantity of the RNA were determined using
a biophotometer (DU 800; Beckman Coulter, Fullerton,
CA).
Rat retinal cDNA was prepared from 2 μg of total
RNA using SuperScript™ reverse transcriptase (RT; Life
Technologies, Grand Island, NY). Briefly, isolated RNA
was incubated with 50 μM oligo (dT) 20, 10 mM dNTP
mix, and DEPC-treated water at 65°C for 5 min. Next,
10 μl of cDNA synthesis mix (10 × RT buffer, 25 mM
MgCl2, 0.1 M DTT, 40 U/μl RNaseOUT, and 200 U/μl
SuperScript™ III RT) were added to the reaction, fol-
lowed by incubation with oligo (dT) 20 at 50°C for
50 min, then incubation with random hexamer at 25°C
for 10 min, and finally incubation at 50°C for another
50 min. The reactions were terminated by treatment at
85°C for 5 min, and the mixtures were chilled. RNase H
was added to each sample, and the mixture was incu-
bated for 20 min at 37°C.
The synthesis of cDNA was achieved using the follow-
ing: CSF-1R sense, 5’-GCCTTTGGTCTGGGCAAA-3’;
CSF-1Rantisense, 5’-AGCCGTGGACTTGAGCATCT-3’;
and TaqMan probe, 5’-FAM-AAGATGCAGTGCT-
GAAGGTGGCTGTG-TAMRA-3’. The primers and
probe were designed using Primer Express software
(ver2.0; PE Applied Biosystems, Foster City, CA). Quan-
titative PCR amplification was carried out on a real-time
PCR machine (Applied Biosystems 7500 real-time PCR
system), using an initial incubation for 2 min at 95°C
followed by 40 cycles of 15 s at 95°C and 45 s at 60°C.
The mRNA level of CSF-1R was standardized against
the b-actin mRNA level in the same RNA sample. Each
experiment was performed three times.
Immunoprecipitation and Western Blotting
Cells were collected and lysed in lysis buffer [50mM Tris-
HCl, pH 7.5, 1mM EDTA, 0.1% SDS, 150 mM NaCl,
5 mM NaF, 0.5% sodium deoxycholate, 1% Nonidet P-40,
and 1% protease inhibitor cocktail (Sigma-Aldrich)]. The
lysates were centrifuged at 14,000 × g for 10 min at 4°C
and precleared by incubation with 25 μl of protein A/G-
Sepharose beads (GE Healthcare, Piscataway, NJ) and
2 μg of normal murine serum at 4°C for 1 h. The pre-
cleared lysates were then mixed with 5 μg of anti-CSF-1R
antibodies and 20 μl of protein A/G-Sepharose beads as
described above and incubated overnight with gentle
rocking at 4°C. The beads were isolated by centrifugation
and washed four times with cell lysis solution. The
bound proteins were subjected to 8% SDS-PAGE and
transferred to a polyvinylidene difluoride (PVDF) mem-
brane (Millipore, Billerica, MA). After incubation for 1 h
in blocking solution (5% nonfat dry milk in 0.1% TBST
buffer), the membrane was incubated overnight at 4°C in
blocking buffer containing the respective antibody (anti-
phospho-CSF-1R(Tyr723),1:200; Cell Signaling Technol-
ogy; anti-CSF-1R, 1:200, Santa Cruz Biotechnology). The
membrane was then washed three times and incubated
with horseradish peroxidase-conjugated goat anti-rabbit
antibodies (1:2,000; Santa Cruz Biotechnology) in blocking
buffer for 2 h at room temperature. The bound antibodies
were detected using an enhanced chemiluminescence sys-
tem (ECL; GE Healthcare) and X-ray film. Densitometric
analysis of each sample was performed using ImageMas-
terRVDS (GE Healthcare).
Enzyme-Linked Immunosorbent Assay (ELISA)
Purified microglial cells were incubated overnight in
24-well plates at 2.5 × 105 cells per well in 1 mL of
serum-free medium with or without graded GA. The
supernatant was collected at the indicated times after
treatment with the conditioned medium from the control
and experimental groups, and the amounts of TNF-a, IL-
1b, and M-CSF were quantified by ELISAs (Biosource,
Inc., Camarillo, CA), in accordance with the manufac-
turer’s instructions. Each experiment was performed
three times.
Statistical Analysis
Statistical analyses were performed using one-way
ANOVA, followed by post-hoc analysis with the Bonfer-
roni (equal variances assumed) or Dunnett’s test (equal
variances not assumed). All quantitative data are pre-
sented as the mean ± SD. Values of P < 0.05 were con-
sidered statistically significant.
Acknowledgements
This work was supported by grants from the National Basic Research
Program of China (973 program), (2007 CB512205), National Basic Research
grants of China (30872825, 2008) and Plan of the Best Disciplines Leaders in
Shanghai (09XD1400900). The authors thank WY, ZSH, XP, and WJH for
skillful technical supports.
Author details
1Department of Opthalmology, EENT Hospital, Eye Institute, Fudan University,
Shanghai, 200031, China. 2Institute of Brain Science, Fudan University,
Shanghai, 200031, China.
Authors’ contributions
LW performed the experiments, designed the protocol, performed the
statistical analysis and drafted the manuscript. XGZ and JCH designed the
protocol and coordinated the study. TJ participated in the microglial culture.
All authors have read and approved the final manuscript.
Liu et al. BMC Cell Biology 2011, 12:5
http://www.biomedcentral.com/1471-2121/12/5
Page 9 of 11
Competing interests
The authors declare that they have no competing interests.
Received: 22 December 2010 Accepted: 25 January 2011
Published: 25 January 2011
References
1. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, Levison SW,
Gardner TW, Bronson SK: The Ins2Akita mouse as a model of early retinal
complications in diabetes. Invest Ophthalmol Vis Sci 2005, 46:2210-2218.
2. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, Levison SW:
Minocycline reduces proinflammatory cytokine expression, microglial
activation, and caspase-3 activation in a rodent model of diabetic
retinopathy. Diabetes 2005, 54:1559-1565.
3. Rungger-Brändle E, Dosso AA, Leuenberger PM: Glial reactivity, an early
feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000,
41:1971-1980.
4. Zeng HY, Green WR, Tso MO: Microglial activation in human diabetic
retinopathy. Arch Ophthalmol 2008, 126:227-232.
5. Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering
the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
6. Garden GA, Möller T: Microglia biology in health and disease. J Neuroimm
Pharmacol 2006, 1:127-137.
7. Kim SU, de Vellis J: Microglia in health and disease. J Neurosci Res 2005,
81:302-313.
8. Wang AL, Yu AC, He QH, Zhu X, Tso MO: AGEs mediated expression and
secretion of TNF alpha in rat retinal microglia. Exp Eye Res 2007,
84:905-913.
9. Ahmed N: Advanced glycation endproducts–role in pathology of
diabetic complications. Diabetes Res Clin Pract 2005, 67:3-21.
10. Negoro H, Morley JE, Rosenthal MJ: Utility of serum fructosamine as a
measure of glycemia in young and old diabetic and nondiabetic
subjects. Am J Med 1988, 85:360-364.
11. Cohen MP, Hud E, Wu VY, Ziyadeh FN: Glycated albumin modified by
Amadori adducts modulates aortic endothelial cell biology. Mol Cell
Biochem 1995, 143:73-79.
12. Cohen MP, Ziyadeh FN, Lautenslager GT, Cohen JA, Shearman CW:
Glycated albumin stimulation of PKC-beta activity is linked to increased
collagen IV in mesangial cells. Am J Physiol 1999, 276:F684-F690.
13. Ruggiero-Lopez D, Rellier N, Lecomte M, Lagarde M, Wiernsperger N:
Growth modulation of retinal microvascular cells by early and advanced
glycation products. Diabetes Res Clin Pract 1997, 34:135-142.
14. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HG,
Schlingemann RO, Tarnow L, Parving HH, Stehouwer CD, van
Hinsbergh VW: Amadori albumin in type 1 diabetic patients: correlation
with markers of endothelial function, association with diabetic
nephropathy, and localization in retinal capillaries. Diabetes 1999,
48:2446-2453.
15. Cohen MP, Hud E, Wu VY, Shearman CW: Amelioration of diabetes-
associated abnormalities in the vitreous fluid by an inhibitor of albumin
glycation. Invest Ophthalmol Vis Sci 2008, 49:5089-5093.
16. Kim J, Kim KS, Shinn JW, Oh YS, Kim HT, Jo I, Shinn SH: The effect of
antioxidants on glycated albumin-induced cytotoxicity in bovine retinal
pericytes. Biochem Biophys Res Commun 2002, 292:1010-1016.
17. Bian ZM, Elner SG, Strieter RM, Glass MB, Lukacs NW, Kunkel SL, Elner VM:
Glycated serum albumin induces chemokine gene expression in human
retinal pigment epithelial cells. J Leukoc Biol 1996, 60:405-414.
18. Bian ZM, Elner VM, Yoshida A, Kunkel SL, Elner SG: Signaling pathways for
glycated human serum albumin-induced IL-8 and MCP-1 secretion in
human RPE cells. Invest Ophthalmol Vis Sci 2001, 42:1660-1668.
19. Brandt R, Landmesser C, Vogt L, Hehmke B, Hanschke R, Kasbohm J,
Hartmann K, Jäger B, Krantz S, Michaelis D: Differential expression of
fructosyllysine-specific receptors on monocytes and macrophages and
possible pathophysiological significance. Diabetologia 1996, 39:1140-1147.
20. Salazar R, Brandt R, Krantz S: Expression of fructosyllysine receptors on
human monocytes and monocyte-like cell lines. Biochim Biophys Acta
1995, 1266:57-63.
21. Salazar R, Brandt R, Krantz S: Binding of Amadori glucose-modified
albumin by the monocytic cell line MonoMac 6 activates protein kinase
C epsilon protein tyrosine kinases and the transcription factors AP-1 and
NF-kappaB. Glycoconj J 2001, 18:769-777.
22. Cohen MP, Shea E, Chen S, Shearman CW: Glycated albumin increases
oxidative stress, activates NF-kappa B and extracellular signal-regulated
kinasee (ERK), and stimulates ERK-dependent transforming growth factor-
beta 1 production in macrophage RAW cells. J Lab Clin Med 2003, 141:242-249.
23. Michaelson MD, Bieri PL, Mehler MF, Xu H, Arezzo JC, Pollard JW, Kessler JA:
CSF-1 deficiency in mice results in abnormal brain development.
Development 1996, 122:2661-2672.
24. Théry C, Hétier E, Evrard C, Mallat M: Expression of macrophage colony-
stimulating factor gene in the mouse brain during development. J
Neurosci Res 1990, 26:129-133.
25. Chitu V, Stanley ER: Colony-stimulating factor-1 in immunity and
inflammation. Curr Opin Immunol 2006, 18:39-48.
26. Murphy GM Jr, Zhao F, Yang L, Cordell B: Expression of macrophage
colony-stimulating factor receptor is increased in the AβPP(V717F)
transgenic mouse model of Alzheimer’s disease. Am J Pathol 2000,
157:895-904.
27. Raivich G, Haas S, Werner A, Klein MA, Kloss C, Kreutzberg GW: Regulation
of MCSF receptors on microglia in the normal and injured mouse
central nervous system: a quantitative immunofluorescence study using
confocal laser microscopy. J Comp Neurol 1998, 395:342-358.
28. Takeuchi A, Miyaishi O, Kiuchi K, Isobe K: Macrophage colony-stimulating
factor is expressed in neuron and microglia after focal brain injury.
J Neurosci Res 2001, 65:38-44.
29. Wang Y, Berezovska O, Fedoroff S: Expression of colony stimulating
factor-1 receptor (CSF-1R) by CNS neurons in mice. J Neurosci Res 1999,
57:616-632.
30. Mitrasinovic OM, Murphy GM Jr: Accelerated phagocytosis of amyloid-
beta by mouse and human microglia overexpressing the
macrophage colony-stimulating factor receptor. J Biol Chem 2002,
277:29889-29896.
31. Mitrasinovic OM, Robinson CC, Tenen DG, Lee YL, Poon C, Murphy GM Jr:
Biolistic expression of the macrophage colony stimulating factor
receptor in organotypic cultures induces an inflammatory response. J
Neurosci Res 2004, 77:420-429.
32. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM: Cytokines in
proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr
Eye Res 1995, 14:1045-1053.
33. Saini A, Liu YJ, Cohen DJ, Ooi BS: Hyperglycemia augments macrophage
growth responses to colony-stimulating factor-1. Metabolism 1996,
45:1125-1129.
34. Imai Y, Kohsaka S: Intracellular signaling in M-CSF-induced microglia
activation: role of Iba1. Glia 2002, 40:164-174.
35. Weinstein JR, Swarts S, Bishop C, Hanisch UK, Möller T: Lipopolysaccharide
is a frequent and significant contaminantin microglial-activating factors.
Glia 2008, 56:16-26.
36. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW,
Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC,
Quinn PG, Sandirasegarane L, Simpson IA: Diabetic retinopathy: seeing
beyond glucose-induced microvascular disease. Diabetes 2006,
55:2401-2411.
37. Kern TS: Contributions of inflammatory processes to the development of
the early stages of diabetic retinopathy. Exp Diabetes Res 2007, 95103.
38. Schalkwijk CG, Lieuw-a-Fa M, van Hinsbergh VW, Stehouwer CD:
Pathophysiological role of Amadori-glycated proteins in diabetic
microangiopathy. Semin Vasc Med 2002, 2:191-197.
39. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR:
Immunohistochemical localization of blood-retinal barrier breakdown in
human diabetics. Am J Pathol 1989, 134:231-235.
40. Vinores SA, McGehee R, Lee A, Gadegbeku C, Campochiaro PA:
Ultrastructural localization of blood-retinal barrier breakdown in diabetic
and galactosemic rats. J Histochem Cytochem 1990, 38:1341-1352.
41. Baynes JW, Thorpe SR, Murtiashaw MH: Nonenzymatic glucosylation of
lysine residues in albumin. Methods Enzymol 1984, 106:88-98.
42. Cohen MP, Ziyadeh FN: Amadori glucose adducts modulate mesangial
cell growth and collagen gene expression. Kidney Int 1994, 45:75-84.
43. Salazar R, Brandt R, Kellermann J, Krantz S: Purification and
characterization of a 200 kDa fructosyllysine-specific binding protein
from cell membranes of U937 cells. Glycoconj J 2001, 17:713-716.
44. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in
mouse type 2 diabetic nephropathy: correlation with diabetic state and
progressive renal injury. Kidney Int 2004, 65:116-128.
Liu et al. BMC Cell Biology 2011, 12:5
http://www.biomedcentral.com/1471-2121/12/5
Page 10 of 11
45. Wautier MP, Boulanger E, Guillausseau PJ, Massin P, Wautier JL: AGEs,
macrophage colony stimulating factor and vascular adhesion molecule
blood levels are increased in patients with diabetic microangiopathy.
Thromb Haemost 2004, 91:879-885.
46. Liu W, Xu GZ, Jiang CH, Da CD: Expression of macrophage colony-
stimulating factor (M-CSF) and its receptor in streptozotocin-induced
diabetic rats. Curr Eye Res 2009, 34:123-133.
47. Calvo CF, Dobbertin A, Gelman M, Glowinski J, Mallat M: Identification of
CSF-1 as a brain macrophage migratory activity produced by astrocytes.
Glia 1998, 24:180-186.
48. Liu W, Brosnan CF, Dickson DW, Lee SC: Macrophage colony-stimulating
factor mediates astrocyte-induced microglial ramification in human fetal
central nervous system culture. Am J Pathol 1994, 145:48-53.
49. Umeda S, Takahashi K, Shultz LD, Naito M, Takagi K: Effects of macrophage
colony-stimulating factor on macrophages and their related cell
populations in the osteopetrosis mouse defective in production of
functional macrophage colony-stimulating factor protein. Am J Pathol
1996, 149:559-574.
50. Shafit-Zagardo B, Sharma N, Berman JW, Bornstein MB, Brosnan CF: CSF-1
expression is up-regulated in astrocyte cultures by IL-1 and TNF and
affects microglial proliferation and morphology in organotypic cultures.
Int J Dev Neurosci 1993, 11:189-198.
51. Hassan NF, Rifat S, Campbell DE, McCawley LJ, Douglas SD: Isolation and
flow cytometric characterization of newborn mouse brain-derived
microglia maintained in vitro. J Leuk Biol 1991, 50:86-92.
52. Roque RS, Caldwell RB: Isolation and culture of retinal microglia. Curr Eye
Res 1993, 12:285-290.
53. Gilcrease MZ, Hoover RL: Activated human monocytes exhibit receptor-
mediated adhesion to a non-enzymatically glycosylated protein
substrate. Diabetologia 1990, 33:329-333.
54. Wolff SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in
diabetes mellitus and ageing. Free Radic Biol Med 1991, 10:339-352.
doi:10.1186/1471-2121-12-5
Cite this article as: Liu et al.: Macrophage colony-stimulating factor and
its receptor signaling augment glycated albumin-induced retinal
microglial inflammation in vitro. BMC Cell Biology 2011 12:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liu et al. BMC Cell Biology 2011, 12:5
http://www.biomedcentral.com/1471-2121/12/5
Page 11 of 11
